Outset Medical
142 hedge funds and large institutions have $2.5B invested in Outset Medical in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 60 increasing their positions, 34 reducing their positions, and 13 closing their positions.
389% more call options, than puts
Call options by funds: $4.11M | Put options by funds: $841K
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
76% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 34
10% more funds holding
Funds holding: 129 → 142 (+13)
8% more capital invested
Capital invested by funds: $2.31B → $2.5B (+$196M)
0.59% more ownership
Funds ownership: 6.71% → 7.3% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
BlackRock
New York
|
+$45.4M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$38.6M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$36.9M |
| 4 |
JP Morgan Chase
New York
|
+$31.3M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$30.9M |
Top Sellers
OM Hedge Fund Activity: Q3 2021 in Review
142 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q3 2021, worth a combined $2.5B — up 8.5% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new OM positions and 13 closed out — a net gain of 13 holders — while 60 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $45.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $100M.
- 142 institutional investors held Outset Medical (OM) as of Q3 2021, up from 129 in Q2 2021.
- Funds reported $2.5B of Outset Medical stock for Q3 2021, up 8.5% quarter-over-quarter.
- 26 funds opened new Outset Medical positions in Q3 2021 and 13 closed out, a net change of +13 holders.
- The largest Outset Medical buyer in Q3 2021 was BlackRock, an estimated $45.4M added.
- The largest Outset Medical seller in Q3 2021 was T. Rowe Price Associates, an estimated $100M sold.
Based on aggregated 13F filings for Q3 2021.